News | March 14, 2026
Curatis and Neupharma strike major deal to bring brain tumor therapy to Japan
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
The conflict is also triggering a widening public health emergency
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings
Germany will be the first launch market
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
The trials, which enrolled over 1,000 patients across 398 sites in 17 countries, showed that the drug was safe and well-tolerated—but ultimately failed to deliver the hoped-for clinical results
The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
The FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial offered confirmatory evidence
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
